Plasma Amylin and Cognition in Diabetes in the Absence and the Presence of Insulin Treatment

Journal of Diabetes & Metabolism
Wei Qiao QiuJames Rosenzweig

Abstract

Plasma amylin is positively associated with cognitive function in humans. Amylin treatment improves memory in Alzheimer's mouse models. However, the relationship between plasma amylin, diabetes and cognition is not clear. In this study we examined the concentration of plasma amylin, its relationship with diabetes and cognition. A cross-sectional, homebound elderly population with data of plasma amylin under fasting condition and cognitive measurements was used. We found that subjects with a long and chronic duration of diabetes were more likely to take insulin treatment and have reduced secretion of amylin. Compared to non-diabetics, diabetic subjects without insulin treatment had a higher concentration, but those with insulin treatment had a lower concentration, of plasma amylin [median (Q1, Q3): 20 (11.0, 36.2) vs. 25.2 (13.2, 50.6) vs. 15.0 (4.9, 33.8), p<0.0001]. In the whole sample vs. in the absence of diabetes, plasma amylin was positively associated with logical memory delayed recall (β= +0.61, SE=0.25, p=0.02 vs. β=+0.80, SE=0.33, p=0.02) and block design (β=+0.62, SE=0.24, p=0.009 vs. β=+0.93, SE=0.31, p=0.003), and negatively associated with Trailmaking A scores (β= -6.21, SE=1.55, p<0.0001 vs. β=-7.51, SE=1.95, p=0....Continue Reading

Citations

Jul 3, 2015·Frontiers in Neuroscience·Thomas A Lutz, Urs Meyer
Apr 24, 2018·Mediators of Inflammation·Kelly N Z FullerJacob M Haus

❮ Previous
Next ❯

Methods Mentioned

BETA
Blood draw
ELISA
PCR
electrophoresis

Related Concepts

Related Feeds

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.